Christopher has made over 1 trades of the Zomedica Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 6,400 units of ZOM stock worth $7,040 on 3 February 2021.
The largest trade he's ever made was selling 6,400 units of Zomedica Pharmaceuticals stock on 3 February 2021 worth over $7,040. On average, Christopher trades about 1,600 units every 0 days since 2020.
You can see the complete history of Mr. Macleod stock trades at the bottom of the page.
Christopher R. MacLeod serves as Independent Director of the Company. Mr. MacLeod is an attorney whose practice is focused on complex business litigation. Since January 2010, Mr. MacLeod has been a founding partner of Cambridge LLP, a Canadian law firm. Mr. MacLeod holds a bachelor’s degree in political science and religious studies from the University of Regina and an LLB from the University of Saskatchewan.
Christopher MacLeod is 50, he's been the Independent Director of Zomedica Pharmaceuticals since 2020. There are 7 older and 4 younger executives at Zomedica Pharmaceuticals. The oldest executive at Zomedica Pharmaceuticals Corp. is Robert W. DiMarzo, 64, who is the Consultant.
Christopher's mailing address filed with the SEC is C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR, MI, 48108.
Over the last 5 years, insiders at Zomedica Pharmaceuticals have traded over $7,040 worth of Zomedica Pharmaceuticals stock and bought 3,375,000 units worth $601,250 . The most active insiders traders include Robert Cohen, Johnny D Powers und Stephanie Morley. On average, Zomedica Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $39,452. The most recent stock trade was executed by Larry C Ii Heaton on 5 September 2024, trading 100,000 units of ZOM stock currently worth $13,000.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Zomedica Pharmaceuticals executives and other stock owners filed with the SEC include: